RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study

URN to cite this document: urn:nbn:de:bvb:355-epub-293079

Beier, Christoph P., Schmid, Christina, Gorlia, Thierry, Kleinletzenberger, Christine, Beier, Dagmar, Grauer, Oliver, Steinbrecher, Andreas, Hirschmann, Birgit, Brawanski, Alexander, Dietmaier, Christopher, Jauch-Worley, Tanja, Kölbl, Oliver, Pietsch, Torsten, Proescholdt, Martin A., Rümmele, Petra, Muigg, Armin, Stockhammer, Günther, Hegi, Monika, Bogdahn, Ulrich and Hau, Peter (2009) RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study. BMC cancer 9, p. 308.

Preview

PDF
Download (233kB)

Date of publication of this fulltext: 16 Jan 2014 11:37

at PubMed

at publisher (via DOI)

Abstract

Together, the investigated combination is tolerable and feasible. Neither the addition of PEG-Dox nor the prolonged administration of Temozolomide resulted in a meaningful improvement of the patient's outcome as compared to the EORTC26981/NCIC-CE.3 data.

Export bibliographical data

Item type:

Article

Date:

2009

Institutions:

Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Hirntumore (ZHT)

Identification Number:

Value	Type
17664483	PubMed ID
10.1186/1471-2407-9-308	DOI

Classification:

Notation	Type
Adolescent	MESH
Adult	MESH
Aged	MESH
Central Nervous System Neoplasms/radiotherapy	MESH
Combined Modality Therapy	MESH
Dacarbazine/analogs & derivatives	MESH
Doxorubicin/analogs & derivatives	MESH
Drug Administration Schedule	MESH
Drug Therapy, Combination	MESH
Drug-Related Side Effects and Adverse Reactions	MESH
Female	MESH
Glioblastoma/radiotherapy	MESH
Humans	MESH
Male	MESH
Middle Aged	MESH
Polyethylene Glycols/adverse effects	MESH
Young Adult	MESH